Snake Venom Peptide Crotalicidin Kills Cancer Cells 17x More Selectively Than Normal Cells
Snake venom peptide crotalicidin (Ctn) kills leukemia cells through dual membrane disruption and intracellular targeting, with 17-fold selectivity for tumor over healthy cells.
Quick Facts
What This Study Found
Ctn and Ctn[15-34] kill leukemia cells via dual membranolytic and intracellular mechanisms, with 17-fold and 7-fold tumor selectivity respectively, and protease stability up to 18-24 hours.
Key Numbers
Selectivity: Ctn 17:1, Ctn[15-34] 7:1; serum stability up to 24h (Ctn) and 18h (fragment)
How They Did This
In-vitro study using flow cytometry, microscopy, and affinity purification proteomics to characterize antitumoral mechanisms and selectivity of Ctn and Ctn[15-34] against pro-monocytic leukemia cells.
Why This Research Matters
Cancer cells that resist conventional drugs may be vulnerable to membrane-disrupting venom peptides that bypass resistance mechanisms — and the high tumor selectivity reduces toxicity concerns.
The Bigger Picture
This study shows venom peptides can be dual-action cancer killers — disrupting membranes AND targeting intracellular pathways — making them harder for cancer cells to resist.
What This Study Doesn't Tell Us
In-vitro study with one leukemia cell line; selectivity ratios may differ across cancer types; in-vivo efficacy and toxicity not tested; mechanism details need further validation.
Questions This Raises
- ?Does the dual mechanism prevent resistance development compared to single-mechanism drugs?
- ?Can Ctn selectivity be further improved by peptide engineering?
- ?How does Ctn perform in vivo against leukemia in animal models?
Trust & Context
- Key Stat:
- 17-fold tumor selectivity Crotalicidin preferentially kills leukemia cells over healthy cells with dual membranolytic and intracellular mechanisms
- Evidence Grade:
- Comprehensive in-vitro mechanistic study with proteomic target identification and selectivity quantification, but limited to one cancer cell line without in-vivo data.
- Study Age:
- Published in 2020; venom-derived anticancer peptides remain an active drug development area.
- Original Title:
- Tumor Cell Attack by Crotalicidin (Ctn) and Its Fragment Ctn[15-34]: Insights into Their Dual Membranolytic and Intracellular Targeting Mechanism.
- Published In:
- ACS chemical biology, 15(11), 2945-2957 (2020)
- Authors:
- Pérez-Peinado, Clara(2), Valle, Javier, Freire, João M, Andreu, David
- Database ID:
- RPEP-05081
Evidence Hierarchy
Frequently Asked Questions
Can snake venom fight cancer?
Crotalicidin from rattlesnake venom kills leukemia cells 17 times more selectively than healthy cells, using both membrane disruption and intracellular targeting mechanisms.
How does crotalicidin kill cancer cells?
Through a dual mechanism: first disrupting the cancer cell membrane, then entering the cell and interfering with DNA metabolism, cell cycle, and apoptosis pathways.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05081APA
Pérez-Peinado, Clara; Valle, Javier; Freire, João M; Andreu, David. (2020). Tumor Cell Attack by Crotalicidin (Ctn) and Its Fragment Ctn[15-34]: Insights into Their Dual Membranolytic and Intracellular Targeting Mechanism.. ACS chemical biology, 15(11), 2945-2957. https://doi.org/10.1021/acschembio.0c00596
MLA
Pérez-Peinado, Clara, et al. "Tumor Cell Attack by Crotalicidin (Ctn) and Its Fragment Ctn[15-34]: Insights into Their Dual Membranolytic and Intracellular Targeting Mechanism.." ACS chemical biology, 2020. https://doi.org/10.1021/acschembio.0c00596
RethinkPeptides
RethinkPeptides Research Database. "Tumor Cell Attack by Crotalicidin (Ctn) and Its Fragment Ctn..." RPEP-05081. Retrieved from https://rethinkpeptides.com/research/perez-peinado-2020-tumor-cell-attack-by
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.